Leadership

Congruence has assembled an outstanding team of experienced drug hunters
who are devoted to developing new medicines for patients in need.

Clarissa Desjardins, Ph.D.
CEO
Link
Charles Grubsztajn, BCL, MBA
COO
Link
Sharath Hegde, Ph.D.
CSO
Link
Michael D. Harvey, Ph.D.
CDO
Link
Frank Taffy, JD
CBO
Link
Edith Bellavance, M.Sc.
Executive Director, DMPK
Link
Katherine Bonter, M.Sc.
Executive Director Intellectual Property
Link
Alex Caron, M.Sc.
Executive Director, Pharmacology
Link
Maximilian Ebert, Ph.D.
Vice President, Computational Molecular Sciences
Link
Lee D. Fader, Ph.D.
Vice President Chemistry
Link
Michael Rock Goldsmith, Ph.D.
Chief Innovation Scientist
Link
Myriam Taillefer, CPA
Vice President of Finance
Link
Roberto Bellini

David Bonita

Zavain Dar

Nathaniel David

Clarissa Desjardins

Daniel Hétu

Didier Leconte

Dion Madsen

Bill Mezzanotte

Investors

Since 2021, Congruence has raised $139.5 million from leading life science and tech-bio investors and tech-bio, including OrbiMed, Dimension, Amplitude, FSTQ, Lumira, IQ, BDC Thrive Venture fund, Silver Arc, Driehaus, and Alexandria.

Partners
Partners